Millions of patients with immune-mediated diseases lack effective treatment options due to the complex and heterogeneous nature of these conditions. Current therapies often provide limited relief or have significant side effects, highlighting the need for more targeted and personalized approaches.

Graph employs an AI-driven precision medicine approach, leveraging perturbation modeling from primary patient cell samples and multi-omics data to develop targeted therapies and biomarkers for immune-mediated diseases. By analyzing patient-specific cellular responses to various stimuli, Graph identifies key drivers of disease and predicts therapeutic efficacy. This enables the development of personalized treatment strategies that address the underlying mechanisms of disease, leading to improved patient outcomes. The platform aims to transform drug discovery and development for immune-mediated diseases by providing a more rational and efficient approach.

Perturbation modeling of primary patient cell samples to capture individual disease heterogeneity

Multi-omics data integration (genomics, transcriptomics, proteomics) for comprehensive disease profiling

AI-driven analysis to identify key disease drivers and predict therapeutic response

Biomarker discovery for patient stratification and treatment monitoring

Targeted therapy development based on patient-specific disease mechanisms

The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions focused on developing novel therapies for immune-mediated diseases.